Full text loading...
- ISSN: 1568-0053
- E-ISSN: 1875-5852
-
The Strategy of Immunologic Control of HIV-1 with Structured Treatment Interruptions (STIs)
- Source: Current Drug Targets - Infectious Disorders, Volume 1, Issue 1, May 2001, p. 11 - 17
-
- 01 May 2001
Abstract
Structured treatment interruptions (STIs) have evolved as an experimental approach of interrupting highly active antiretroviral therapy (HAART) similar to cycles of cancer chemotherapy in order to develop immune control of HIV-1. There are multiple, on-going clinical trials examining interruptions in antiviral therapy with and without immune-based therapies. If successful in developing immune control, STIs may be clinically useful but require large scale clinical trials to prove their utility and safety.
© Bentham Science Publishers